Finally, not all studies provided detailed information regarding the molecular profile of the DCIS in relation to ER and HER2 status and the proportion of HER2-positive disease (46%) was higher in the pooled analysis than encountered in clinical practice. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.